Description: Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Home Page: www.karunatx.com
KRTX Technical Analysis
99 High Street
Boston,
MA
02110
United States
Phone:
857 449 2244
Officers
| Name | Title |
|---|---|
| Dr. Steven M. Paul M.D. | CEO, Pres & Chairman |
| Dr. Andrew Craig Miller | Co-Founder & COO |
| Dr. Troy A. Ignelzi | CFO & Sec. |
| Dr. Stephen K. Brannan | Chief Medical Officer |
| Ms. Charmaine Lykins | Chief Commercial Officer |
| Dr. Alan Breier | Chair of Scientific Advisory Board & Chief Clinical Advisor |
| Dr. Ronald N. Marcus M.D. | Sr. VP of Medical |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.9374 |
| Price-to-Sales TTM: | 162.3836 |
| IPO Date: | 2019-06-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 118 |